|1st December 2020||Huw M. Nash||2,719||Open or private sale||$49.19||$133,743.53|
|1st December 2020||Huw M. Nash||100||Open or private sale||$51.45||$5,145.00|
|1st December 2020||Huw M. Nash||2,481||Open or private sale||$50.02||$124,103.09|
|1st December 2020||Huw M. Nash||5,700||Exercise of derivative||$2.19||$12,483.00|
|1st December 2020||Huw M. Nash||400||Open or private sale||$52.72||$21,088.00|
|27th November 2020||Edward M. Md Kaye||12,152||Open or private sale||$50.00||$607,600.00|
|25th November 2020||Edward M. Md Kaye||12,848||Open or private sale||$50.00||$642,400.00|
|24th November 2020||Tree Partners Iv, L.P. Apple||375,000||Open or private purchase||$39.00||$14,625,000.00|
|24th November 2020||Seth Loring Harrison||375,000||Open or private purchase||$39.00||$14,625,000.00|
|10th November 2020||Huw M. Nash||13,414||Exercise of derivative||$2.19||$29,376.66|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.